Amitkumar Mehta
University of Alabama at Birmingham
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amitkumar Mehta as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04975555 · Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell TherapyUniversity of Alabama at Birmingham · completed · Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin · principal investigator
- Ph1/Ph2NCT04692155 · Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)University of Alabama at Birmingham · terminated · Mantle Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- NCTN Deep South Research ConsortiumUG1CA233330 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2019 to 2026 · $327,630 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Protocol and Data ManagementP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2023 to 2024 · $389,743 awarded in 2024Same name and institution; not confirmed by an ID
- NCTN Deep South Research ConsortiumU10CA180855 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2018 · $436,712 awarded in 2018Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:04 UTC. The ranking covers the 200 most relevant of 216 PubMed records, and a shared surname and initials can bring in a namesake. All 216 on PubMed
- Remdesivir for the Treatment of Covid-19 - Final Report.N Engl J Med · 20205,332 citationsRCR 287.3
- 2,107 citationsRCR 87.1
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.N Engl J Med · 20211,413 citationsRCR 83.9
- Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis.Proc Natl Acad Sci U S A · 2016795 citationsRCR 31.3
- 465 citationsRCR 19.0
- Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.Eur Heart J · 2003357 citationsRCR 8.5
- A randomized, controlled study of a mandibular advancement splint for obstructive sleep apnea.Am J Respir Crit Care Med · 2001309 citationsRCR 11.4
- 259 citationsRCR 7.3
- Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial.Nat Cancer · 2021251 citationsRCR 11.9
- 240 citationsRCR 7.0